The global gabapentin market size is estimated at USD 3.07 billion in 2025 and is forecasted to worth around USD 5.23 billion by 2034, accelerating at a CAGR of 6.07% from 2025 to 2034. The North America gabapentin market size crossed USD 1.07 billion in 2024 and is expanding at a CAGR of 6.10% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Gabapentin Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Gabapentin Market Revenue and Volume Forecast, by Dosage
8.1.1. Tablet
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Capsule
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Oral Solution
8.1.3.1. Market Revenue and Volume Forecast
9.1. Gabapentin Market Revenue and Volume Forecast, by Type
9.1.1. Generic
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Branded
9.1.2.1. Market Revenue and Volume Forecast
10.1. Gabapentin Market Revenue and Volume Forecast, by Application
10.1.1. Epilepsy
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Neuropathic Pain
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Restless Legs Syndrome
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. Gabapentin Market Revenue and Volume Forecast, by Distribution Channel
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Pharmacy
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Dosage
12.1.2. Market Revenue and Volume Forecast, by Type
12.1.3. Market Revenue and Volume Forecast, by Application
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Dosage
12.1.5.2. Market Revenue and Volume Forecast, by Type
12.1.5.3. Market Revenue and Volume Forecast, by Application
12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Dosage
12.1.6.2. Market Revenue and Volume Forecast, by Type
12.1.6.3. Market Revenue and Volume Forecast, by Application
12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Dosage
12.2.2. Market Revenue and Volume Forecast, by Type
12.2.3. Market Revenue and Volume Forecast, by Application
12.2.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Dosage
12.2.5.2. Market Revenue and Volume Forecast, by Type
12.2.5.3. Market Revenue and Volume Forecast, by Application
12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Dosage
12.2.6.2. Market Revenue and Volume Forecast, by Type
12.2.6.3. Market Revenue and Volume Forecast, by Application
12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Dosage
12.2.7.2. Market Revenue and Volume Forecast, by Type
12.2.7.3. Market Revenue and Volume Forecast, by Application
12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Dosage
12.2.8.2. Market Revenue and Volume Forecast, by Type
12.2.8.3. Market Revenue and Volume Forecast, by Application
12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Dosage
12.3.2. Market Revenue and Volume Forecast, by Type
12.3.3. Market Revenue and Volume Forecast, by Application
12.3.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Dosage
12.3.5.2. Market Revenue and Volume Forecast, by Type
12.3.5.3. Market Revenue and Volume Forecast, by Application
12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Dosage
12.3.6.2. Market Revenue and Volume Forecast, by Type
12.3.6.3. Market Revenue and Volume Forecast, by Application
12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Dosage
12.3.7.2. Market Revenue and Volume Forecast, by Type
12.3.7.3. Market Revenue and Volume Forecast, by Application
12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Dosage
12.3.8.2. Market Revenue and Volume Forecast, by Type
12.3.8.3. Market Revenue and Volume Forecast, by Application
12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Dosage
12.4.2. Market Revenue and Volume Forecast, by Type
12.4.3. Market Revenue and Volume Forecast, by Application
12.4.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Dosage
12.4.5.2. Market Revenue and Volume Forecast, by Type
12.4.5.3. Market Revenue and Volume Forecast, by Application
12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Dosage
12.4.6.2. Market Revenue and Volume Forecast, by Type
12.4.6.3. Market Revenue and Volume Forecast, by Application
12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Dosage
12.4.7.2. Market Revenue and Volume Forecast, by Type
12.4.7.3. Market Revenue and Volume Forecast, by Application
12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Dosage
12.4.8.2. Market Revenue and Volume Forecast, by Type
12.4.8.3. Market Revenue and Volume Forecast, by Application
12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Dosage
12.5.2. Market Revenue and Volume Forecast, by Type
12.5.3. Market Revenue and Volume Forecast, by Application
12.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Dosage
12.5.5.2. Market Revenue and Volume Forecast, by Type
12.5.5.3. Market Revenue and Volume Forecast, by Application
12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Dosage
12.5.6.2. Market Revenue and Volume Forecast, by Type
12.5.6.3. Market Revenue and Volume Forecast, by Application
12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1. Pfizer Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Mylan N.V.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sun Pharmaceutical Industries Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Aurobindo Pharma Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Novartis AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Amneal Pharmaceuticals, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Glenmark Pharmaceuticals Ltd.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Hikma Pharmaceuticals PLC
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Lupin Limited
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample